These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26014300)

  • 1. Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies.
    Tosi D; Laghzali Y; Vinches M; Alexandre M; Homicsko K; Fasolo A; Del Conte G; Durigova A; Hayaoui N; Gourgou S; Gianni L; Mollevi C
    J Clin Oncol; 2015 Jul; 33(19):2158-65. PubMed ID: 26014300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials.
    Hansen AR; Cook N; Ricci MS; Razak A; Le Tourneau C; McKeever K; Roskos L; Dixit R; Siu LL; Hinrichs MJ
    Oncologist; 2015 Jun; 20(6):653-9. PubMed ID: 25964306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
    Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
    Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.
    Viala M; Vinches M; Alexandre M; Mollevi C; Durigova A; Hayaoui N; Homicsko K; Cuenant A; Gongora C; Gianni L; Tosi D
    Br J Cancer; 2018 Mar; 118(5):679-697. PubMed ID: 29438365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials.
    Le Tourneau C; Stathis A; Vidal L; Moore MJ; Siu LL
    J Clin Oncol; 2010 Mar; 28(8):1401-7. PubMed ID: 20124167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013.
    Suh HY; Peck CC; Yu KS; Lee H
    Drug Des Devel Ther; 2016; 10():4005-4016. PubMed ID: 27994442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric phase I trials in oncology: an analysis of study conduct efficiency.
    Lee DP; Skolnik JM; Adamson PC
    J Clin Oncol; 2005 Nov; 23(33):8431-41. PubMed ID: 16293874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors.
    Doi T; Murakami H; Ohtsu A; Fuse N; Yoshino T; Yamamoto N; Boku N; Onozawa Y; Hsu CP; Gorski KS; Friberg G; Kawaguchi T; Sasaki T
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):733-41. PubMed ID: 21161528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
    Postel-Vinay S; Collette L; Paoletti X; Rizzo E; Massard C; Olmos D; Fowst C; Levy B; Mancini P; Lacombe D; Ivy P; Seymour L; Le Tourneau C; Siu LL; Kaye SB; Verweij J; Soria JC
    Eur J Cancer; 2014 Aug; 50(12):2040-9. PubMed ID: 24880774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.
    Vonderheide RH; Flaherty KT; Khalil M; Stumacher MS; Bajor DL; Hutnick NA; Sullivan P; Mahany JJ; Gallagher M; Kramer A; Green SJ; O'Dwyer PJ; Running KL; Huhn RD; Antonia SJ
    J Clin Oncol; 2007 Mar; 25(7):876-83. PubMed ID: 17327609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive dose finding for phase I clinical trials of drugs used for chemotherapy of cancer.
    Potter DM
    Stat Med; 2002 Jul; 21(13):1805-23. PubMed ID: 12111891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial design: are new methodologies being put into practice?
    Dent SF; Eisenhauer EA
    Ann Oncol; 1996 Aug; 7(6):561-6. PubMed ID: 8879368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.
    Muller PY; Brennan FR
    Clin Pharmacol Ther; 2009 Mar; 85(3):247-58. PubMed ID: 19177065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials.
    Gupta S; Hunsberger S; Boerner SA; Rubinstein L; Royds R; Ivy P; LoRusso P
    J Natl Cancer Inst; 2012 Dec; 104(24):1860-6. PubMed ID: 23169991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity.
    Seymour L; Eisenhauer E
    Cancer Chemother Pharmacol; 2001; 47(1):2-10. PubMed ID: 11221956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection.
    Saber H; Del Valle P; Ricks TK; Leighton JK
    Regul Toxicol Pharmacol; 2017 Nov; 90():144-152. PubMed ID: 28887049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
    Tijink BM; Buter J; de Bree R; Giaccone G; Lang MS; Staab A; Leemans CR; van Dongen GA
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6064-72. PubMed ID: 17062682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
    Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-dose-cohort designs in cancer phase I trials.
    Huang B; Chappell R
    Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.